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Abstract
Background: Despite the obvious survival benefit compared to that among waitlist patients, outcomes of positive
crossmatch kidney transplantation (KT) are generally inferior to those of human leukocyte antigen (HLA)-compatible
KT. This study aimed to compare the outcomes of positive complement-dependent cytotoxicity (CDC) crossmatch
(CDC + FC+) and positive flow cytometric crossmatch (CDC-FC+) with those of HLA-compatible KT (CDC-FC-) after
successful desensitization.
Methods: We retrospectively analyzed 330 eligible patients who underwent KTs between June 2011 and August
2017: CDC-FC- (n = 274), CDC-FC+ (n = 39), and CDC + FC+ (n = 17). Desensitization protocol targeting donor-
specific antibody (DSA) involved plasmapheresis, intravenous immunoglobulin (IVIG), and rituximab with/without
bortezomib for positive-crossmatch KT.
Results: Death-censored graft survival and patient survival were not different among the three groups. The median
estimated glomerular filtration rate was significantly lower in the CDC + FC+ group than in the compatible group at
6 months (P < 0.001) and 2 years (P = 0.020). Biopsy-proven rejection within 1 year of CDC-FC-, CDC-FC+, and CDC +
FC+ were 15.3, 28.2, and 47.0%, respectively. Urinary tract infections (P < 0.001), Pneumocystis jirovecii pneumonia
(P < 0.001), and cytomegalovirus viremia (P < 0.001) were more frequent in CDC-FC+ and CDC + FC+ than in CDC-
FC-.
Conclusions: This study showed that similar graft and patient survival was achieved in CDC-FC+ and CDC + FC+ KT
compared with CDC-FC- through DSA-targeted desensitization despite the higher incidence of rejection and
infection than that in compatible KT.
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Background
Patients undergoing positive-crossmatch kidney transplant-
ation (KT) from living donors have the advantage of sur-
vival compared to highly sensitized patients on waitlists [1].
However, there is inevitable immunologic risk despite
rigorous pre- or posttransplant immunosuppression during
desensitization. Several studies have reported a higher graft
failure and mortality after positive-crossmatch KT than
after compatible KT [2–4]; hence, only certain centers per-
form positive-crossmatch KT in the United States [5].
Methods based on complement-dependent cytotoxicity
(CDC) crossmatch for identifying and characterizing
anti-HLA antibody, such as the single-antigen assay and
the C1q assay, have recently been developed and used
clinically [6, 7]. Since the introduction of more sensitive
methods such as flow cytometry (FC) crossmatch and
the single antigen assay (SAA) using Luminex technol-
ogy, the importance of quantifying antigen strength has
been emphasized [6, 8–12]. Furthermore, baseline
donor-specific antibody (DSA) titers are associated with
the outcome of positive-crossmatch KT [13]. However,
most studies on positive-crossmatch KT so far did not
examine preoperative DSA titers, but rather involved
retrospective examinations, thus not indicating DSA to
be an appropriate target for successful desensitization.
A recent study reported a similar graft and patient sur-
vival rate between positive-crossmatch living-donor KT
(LDKT) and compatible KT upon desensitization with a
risk-stratified protocol [14]; however, the study involved
a small cohort undergoing CDC-positive KT. Hence, this
study aimed to evaluate post-transplant outcomes of
CDC-positive (CDC + FC+) and FC-positive (CDC-FC+)
KT using a DSA-targeted desensitization protocol and
compare these outcomes with those of compatible KT
(CDC-FC-).
Methods
Study population
We retrospectively assessed 691 consecutive living donor
KT recipients at Severance hospital in Seoul, Korea from
June 2011, when Luminex-based SAA was initiated, to
August 2017. Patients under 18 years of age, those re-
ceiving kidney transplants from HLA-identical siblings,
ABO incompatible KT, those taking cyclosporin primar-
ily as an immunosuppressant, and those lacking findings
of pretransplant DSA or FC were excluded. Cases of
negative crossmatch with DSA (n = 21) were excluded in
accordance with the recent report on non-inferior graft
survival [15]. Furthermore, patients presenting positive
T-cell but negative B-cell crossmatches and positive FC
without DSA were excluded owing to potential technical
errors. Finally, 330 eligible patients were divided into
three groups; CDC-FC-, CDC-FC+, and CDC + FC+
(Fig. 1).
Crossmatch and detection of DSA
Throughout the study, CDC and FC crossmatch and
SAA were screened for all KT recipients with their po-
tential living donors and repeated 1 or 2 days before
transplantation. T-cell CDC was performed with anti-
human globulin test and B-cell CDC was performed by
warm-method. The results were recorded as the max-
imum titer presenting more than 11% of cell lysis. FC
crossmatch using FACS Canto II (Beckton Dickinson,
San Jose, CA, USA) was considered positive when the
median fluorescence intensity (MFI) ratio was greater
than 2.0. SAA was performed using two reagents during
the study period: 1. Lifecodes LSA class I and class II
(Gen-Probe Transplant Diagnostics, Inc., Stamford, CT,
USA) from Jun 2011 to Dec 2014; 2. LABScreen Single
Antigen class I and class II (One Lambda, Canoga Park,
Fig. 1 Study population. CDC, complement dependent cytotoxicity; DSA, donor specific antibody; FC, flow cytometry; HLA, human leukocyte
antigen; LDKT, living donor kidney transplantation
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CA, USA) from Jan 2015 to Aug 2017. Antibodies
against donor HLA-A, B, DR, and DQ were character-
ized, and the strength of each DSA was determined at
the maximum MFI value. An MFI of > 1000 was consid-
ered positive. We assessed DSA in all recipients before
KT. After transplantation, DSA was checked only when
rejection was suspected until September 2015 due to
cost issue. Since then, SAA for the detection of DSA has
been covered by national insurance in our country and
we checked DSA at least once a year regardless of acute
rejection. For CDC-FC+ and CDC + FC+ groups, routine
DSA assessment was performed more frequently accord-
ing to pretransplant antigen strength and clinical course,
at least every 3months during 1 posttransplant year.
C1q binding ability of anti-HLA DSA was examined in
accordance with a previously reported method (One
Lambda) [7].
Desensitization protocols and immunosuppression
Pretransplant desensitization for positive-crossmatch KT
at our institution involves plasmapheresis (PP)/low dose
intravenous immunoglobulin (IVIG, 100mg/kg per
cycle) and rituximab (375mg/m2) (Additional file 1: Fig-
ure S1 and Additional file 2: Figure S2). For CDC-FC+,
PP/IVIG were administered 3–4 times 1 week before
surgery. Negative conversion upon FC was considered
an indicator of successful desensitization. However,
rituximab usually results in false-positive B-cell cross-
match. Therefore, decisions regarding successful
desensitization were primarily based on the outcomes of
the SAA, especially for patients with class II DSA.
For CDC + FC+, a 2–3-week desensitization schedule
was designed on the basis of the initial CDC titer and
DSA titer. Rituximab (375 mg/m2) and PP/IVIG were
administered 3 or 4 times a week, and the immunologic
status was re-assessed via repeated CDC and SAA, with
appropriate modifications in the desensitization sched-
ule. The targets were T-cell CDC-negativity and an MFI
< 5000 of immunodominant DSA during the initial
period. However, we subsequently progressed to trans-
plantation with a much higher MFI value of DSA if
enough responsiveness to desensitization was confirmed
through negative conversion of crossmatch or C1q bind-
ing activity. Since June 2015, bortezomib, a proteasome
inhibitor, has been administered to CDC + FC+ patients
who did not respond to rituximab and 3–4 doses of PP/
IVIG. Four doses of bortezomib were administered (1.3
mg/m2 per dose) for 2 weeks during desensitization.
Usually, total 6–10 cycles of PP with IVIG (100 mg/kg
per cycle) were performed for CDC + FC+ patients be-
fore KT.
Instead of basiliximab which is used for induction in
negative-crossmatch KT, we routinely used anti-
thymocyte globulin (ATG; 1.5 mg/kg) for 1–4 days after
KT for positive-crossmatch KTs. Alike negative-
crossmatch KT, tacrolimus-based triple immunosuppres-
sive drugs were used for maintenance (tacrolimus, myco-
phenolate mofetil [MMF] and steroid), and the target
trough levels of tacrolimus were 5–10 ng/ml during the
first month after KT, followed by 3–7 ng/ml. MMF was
initiated before transplantation at an initial dose of
1000–2000 mg/d. Steroid was administered from the day
of transplantation at 500–1000mg of intravenous meth-
ylprednisolone; thereafter, the dosage was tapered to that
of oral prednisolone.
Using these protocols, we performed desensitization in
21 CDC + FC+ patients, but 4 were not able to undergo
KT because of a sustained high titer of T-cell CDC or
C1q positivity despite bortezomib administration. None
of the CDC-FC+ patients failed to undergo KT.
Analysis of clinical outcomes
The primary end points were death-censored graft sur-
vival and patient survival. Graft failure was defined as
returning to dialysis or renal re-transplantation. Second-
ary end points were biopsy-proven rejection (BPAR),
graft function and infectious complications. Renal biopsy
was performed only when graft rejection was clinically
suspected based on increased serum creatinine or pro-
teinuria, in accordance with our hospital policy. BPAR
was confirmed by transplant pathologists at our institu-
tion and antibody mediated rejection (ABMR) or T-cell
mediated rejection (TCMR) was diagnosed in accord-
ance with Banff 2007 classification [16]. Allograft func-
tion was assessed on the basis of eGFR calculated using
the Chronic Kidney Disease Epidemiology formula [17].
For comparisons at each time point, we considered
eGFRs of the patients with graft failure as zero regard-
less of their follow-up status to minimize bias.
We routinely screened for cytomegalovirus (CMV)
viremia (CMV DNA > 1000 copies/ml) and BK virus
(BKV) viremia (BKV DNA > 10,000 copies/ml) every 3–
6 months for the first year and then annually among all
patients. CMV was checked whenever the patient had
fever. In case of positive-crossmatch KT, CMV was
monitored every week for 1 month, then every 3–6
months unless CMV viremia was confirmed. No routine
prophylaxis against CMV infections was administered
but CMV was managed by preemptive strategy [18].
Prophylactic trimethoprim-sulfamethoxazole was admin-
istered for Pneumocystis jirovecii pneumonia (PJP) for a
minimum of 6 months. For fungal prophylaxis, 4 ml ny-
statin was orally administered four times a day for 12
months. Urinary tract infection (UTI), pneumonia,
bacteremia, and intraabdominal infection were consid-
ered only when pathogens were identified with corre-
lated symptoms. Herpes zoster was diagnosed on the
basis of typical skin lesions.
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Statistical analysis
Data of categorical variables were shown as numbers
(frequencies), and chi square test or Fisher’s exact test
were used when appropriate. For the comparison of con-
tinuous variables, the Kruskal–Wallis test was used, and
data were expressed as median (interquartile range
[IQR]). Post hoc analysis was conducted with Bonferro-
ni’s method for the inter-group comparison of eGFR. To
confirm the independent association between cross-
match positivity and eGFR, linear regression was applied
for confounders. Survival outcomes were compared by
Kaplan–Meier survival curves with log-rank tests and
also adjusted using cox regression analysis. All analyses
were performed using a standard software (SPSS v23.0;
IBM, Armonk, NY, USA), and P < 0.05 was considered
statistically significant.
Results
Baseline characteristics of patients
Among 330 LDKT patients, 274 were CDC-FC-, 39 were
CDC-FC+, and 17 were CDC + FC+. As shown in
Table 1, age of recipients and donors was similar in all
groups. Recipients in the CDC-FC+ and CDC + FC+
groups displayed female predominance compared to
those in the control group and vice versa with respect to
donor sex. The duration of pretransplant dialysis was
similar; however, it was greater in cases of re-
transplantation in CDC-FC+ and CDC + FC+ groups
than in the control group. Pretransplant diabetes and
cardiovascular disease, which defined as myocardial in-
farction, coronary artery revascularization and stroke,
showed similar incidence among the three groups.
Immunologic status
Table 2 shows the immunologic status before and after
desensitization in positive-crossmatch groups. In the
CDC-FC+ group, 53.9% patients were positive for B-cell
FC, and 46.1% patients were positive for both T- and B-
cell FC. The median MFI ratio was 3.6 (maximum 18.3)
for T-cell FC and 8.0 (maximum 53.3) for B-cell FC. Be-
fore desensitization, there was a median of 2 DSA speci-
ficities per patient (IQR, 1–3), and the most frequent
type of immunodominant DSA was anti-HLA DR
(56.4%). Median MFI for immunodominant DSA was
4219 (IQR, 2357–10,000; maximum, 12,802). After
desensitization with a median of three doses of PP/IVIG
(IQR, 3–4), DSA was obliterated in 30.8% patients, and
the median MFI for immune-dominant DSA declined to
1902 (IQR, 0–4294; maximum, 11,979).
In the CDC + FC+ group, 64.7% patients were positive
for B-cell CDC, and 35.3% patients were positive for
both T- and B-cell CDC. The maximum titer of CDC
positivity was 1:32 for both T- and B-cell crossmatches.
There was a median of 5 DSA specificities per patient
(IQR 5–6), and the most frequent type of immunodomi-
nant DSA was also anti-HLA DR (52.9%). The median
MFI for immunodominant DSA was 10,951 (IQR, 5732–
14,724; maximum, 18,056). After desensitization with a
median of 6 doses and maximum of 11 doses of PP/
IVIG, DSA was obliterated in 11.8% of recipients and
the median MFI for immunodominant DSA decreased
to 4379 (IQR, 1492–10,457; maximum, 19,235). We
assessed the C1q-binding ability in 16 subsequent cases
before and after desensitization. Nine patients presented
C1q-binding DSA before desensitization. Two patients
with sustained C1q positivity after 1 or 2 weeks of
desensitization received 4 doses of bortezomib before
transplantation. Eventually, 8 of 9 (88.8%) patients pre-
sented negative conversion of C1q binding ability, al-
though DSA was still positive with considerable MFI
value (minimum, 2259; maximum, 19,235).
Graft and patient survival
During a median follow-up of 37 (IQR, 22–52) months,
12 cases of death-censored graft failure were noted. The
causes of graft failure were acute ABMR (5 CDC-FC-, 1
CDC-FC+), chronic ABMR (2 CDC-FC-, 1 CDC-FC+,
and 1 CDC + FC+), acute tubular injury (1 CDC-FC-), or
non-compliance (1 CDC-FC-). Four patients died of
acute cerebral infarction (n = 1), gastrointestinal bleeding
(n = 2), or hematologic malignancy (n = 1).
On Kaplan Meier estimation of 5-year survival (Fig. 2),
death-censored graft survival rates were 95.3% vs. 93.6%
vs. 85.3% for CDC-FC-, CDC-FC+, and CDC + FC+, re-
spectively, with no significant difference among them
(P = 0.598). However, rejection-free graft survival was
significantly lower in the CDC + FC+ group than in the
other two groups (80.1% vs. 73.5% vs. 34.7% for CDC-
FC-, CDC-FC+, and CDC + FC+, respectively; P < 0.001).
Patient survival did not differ significantly among the
Table 1 Baseline characteristics
Variables CDC − FCM−
(n = 274)
CDC − FCM+
(n = 39)
CDC + FC+
(n = 17)
P
Age, years 48 (36–55) 52 (45–57) 46 (41–56) 0.059
Sex, males 178 (65.0%) 6 (15.4%) 4 (2.1%) < 0.001
Donor age, years 45 (34–52) 43 (33–53) 41 (29–49) 0.647
Donor sex, males 111 (40.5%) 24 (61.5%) 5 (29.4%) 0.004
Dialysis duration 0.228
Preemptive 95 (34.7%) 11 (28.2%) 4 (23.5%)
≤ 1 year 118 (43.1%) 13 (33.3%) 8 (47.1%)
> 1 year 61 (22.3%) 15 (38.5%) 5 (29.4%)
Retransplantation 12 (4.4%) 6 (15.4%) 5 (29.4%) < 0.001
Pretransplant DM 73 (26.0%) 13 (33.3%) 2 (11.8%) 0.245
Pretransplant CVD 20 (7.3%) 3 (7.7%) 1 (5.9%) 0.971
CDC Complement dependent cytotoxicity, FC Flow cytometry
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three groups (P = 0.524), although events were too small
to draw statistical conclusion.
There was no significant risk factor for death-censored
graft survival in Cox analysis so we adjusted it with co-
variates which showed difference in demographics
among three groups such as age, sex, donor sex, retrans-
plantation. Patient survival and rejection-free survival
was adjusted with factors of which P value was under
0.10 in univariate analysis; age and donor age for patient
survival, donor age and dialysis duration for rejection-
free graft survival. After adjustment, crossmatch positiv-
ity was still not associated with death-censored graft sur-
vival and patient survival. However, CDC + FC+ versus
CDC-FC- (HR 5.29, 95% CI 2.84–987; P < 0.001) was in-
dependent risk factor for rejection-free graft survival
after adjustment. Full results of Cox analysis are pro-
vided by Additional file 3: Table S1-S3.
Graft function
Figure 3 shows the distribution of eGFR during 5 years
of follow-up. The CDC-FC- and CDC-FC+ groups
showed a median eGFR of > 60ml/min/1.73 m2
throughout the study period, although it slightly de-
creased with time. In the CDC + FC+ group, however,
median eGFR declined to < 60 at 3 years and < 40 from
the fourth year after KT. Furthermore, eGFRs of the
CDC + FC+ group were lower than those of the other
two groups throughout the follow-up period, although
they differed significantly between the CDC-FC- and
CDC + FC+ groups at 6 months (P = 0.037), 2 years (P =
0.038), and 3 years (p = 0.050). After adjustment with sig-
nificantly associated factors in univariate analysis (sex,
donor age and donor sex for eGFR at 6 months and 2
years; donor age for eGFR at 3 years), CDC + FC+ versus
CDC-FC- was independently associated with eGFR at 6
months (β = − 8.18, P = < 0.001) and that at 2 years (β =
− 5.85, P = 0.020).
Biopsy-proven acute rejection within 1 year after
transplantation
During posttransplant year 1, BPAR occurred in 42
CDC-FC- (15.3%) patients, 11 CDC-FC+ (28.2%) pa-
tients, and 8 CDC + FC+ (47.0%) patients. Although the
number of rejections of crossmatch positive groups was
Table 2 Immunologic details before and after desensitization
Variables CDC − FC+
(n = 39)
CDC + FC+
(n = 17)
FC positivity, % (B / T and B) 53.9 / 46.1 –
FC MFI ratio
T cell positive (n = 21), median (IQR) 3.6 (2.9–6.8) Max 18.3 –
B cell positive (n = 39), median (IQR) 8.0 (4.4–17.4) Max 53.3 –
CDC positivity, % (B / T and B) – 64.7 / 35.3
CDC titer
T cell (AHG phase), number (1:2 / 1:4 / 1:8 / 1:32) – 2 / 1 / 2 / 1
B cell (Warm phase), number (1:1 / 1:2 / 1:4 / 1:32) – 3 / 6 / 7 / 1
Number of Pretransplant PP + IVIG, median (IQR) 3 (3–4) Max 8 6 (4–7) Max 11
Pre-desensitization DSA
HLA Class, % (I / II / I + II) 17.9 / 53.8 / 28.3 17.6 / 35.3 / 47.1
Number, median (IQR) 2 (1–3) 5 (5–6)
Immunodominant DSA, % (A / B / DR / DQ) 12.8 / 15.4 / 56.4 / 15.4 11.9 / 17.6/ 52.9 / 17.6
Immunodominant MFI, median (IQR) 4219 (2357–10000) Max 12802 10951 (5732–14724) Max 18056
Sum of MFI, median (IQR) 6577 (3686–13580) Max 45735 14663 (7818–24202) Max 66434
Positive for C1q binding assay Not examined 9 of 16, not examined in 1
Post-desensitization DSA
HLA Class, % (None / I / II / I + II) 30.8 / 12.8 / 46.2 / 10.3 11.8 / 23.5 / 41.2 / 23.5
Number, median (IQR) 1 (0–2) 2 (1–3)
Immunodominant DSA, % (None/A / B / DR / DQ) 30.8 / 7.7 / 10.3 / 41.0 / 10.2 11.8 / 11.8 / 11.8 / 52.8 / 11.8
Immunodominant MFI, median (IQR) 1902 (0–4294) Max 11979 4379 (1492–10457) Max 19235
Sum of MFI, median (IQR) 2685 (0–5811) Max 32811 5250 (2264–15,844) Max 36252
Positive for C1q binding assay Not examined 0 of 16, not examined in 1
ATG Anti-thymocyte globulin, CDC Complement dependent cytotoxicity, DSA Donor-specific antibody, FC Flow cytometry, HLA Human leukocyte antigen, IVIG
Intravenous immunoglobulin, MFI Median fluorescent intensity, PP Plasmapheresis
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too small to compare statistically, details regarding the
first occurrence of BPAR and corresponding rescue
treatment are compared in Table 3. The median dur-
ation from KT to BPAR was significantly shorter among
CDC-FC+ (9 days; IQR, 5–31) and CDC + FC+ (14 days;
IQR, 5–38) patients than in CDC-FC- patients (42 days;
IQR, 11–109; P = 0.035). Among BPARs, ABMR was
42.9% and TCMR was 57.1% in CDC-FC- patients, while
most types of rejections were ABMR in CDC-FC+
(90.9%) and CDC + FC+ (100%). Over half of the cases
of rejection in the CDC-FC- group received only a ster-
oid pulse or additional ATG as rescue treatment, while
most patients in the CDC-FC+ (100%) and CDC + FC+
(75.0%) groups received PP/IVIG. Three (27.3%) patients
in the CDC-FC+ and 5 (62.5%) in the CDC + FC+ group
received PP/IVIG along with 4 doses of bortezomib
upon DSA detection at high MFI or severe deterioration
of allograft function.
Infectious complications within 1 year after
transplantation
As shown in Table 4, the occurrence rate of urinary tract
infection (7.7% vs. 51.3% vs. 23.5%, P < 0.001) was signifi-
cantly higher in CDC-FC+ and CDC + FC+ groups than
in the controls. Bacteremia (2.6% vs. 12.8% vs. 0%) and
intraabdominal infection (0.7% vs. 7.7% vs. 0%, P =
0.036) were significantly more frequent in CDC-FC+ pa-
tients than in the other groups. CDC + FC+ patients
Fig. 2 Comparison of (a) death censored graft survival, (b) rejection free survival, and (c) patient survival. CDC, complement dependent
cytotoxicity; FC, flow cytometry.
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Fig. 3 Graft function at each time point during 5 years of follow up. Red line means median value of eGFR. When graft failure occurred, eGFR
was counted as zero. The differences in median eGFR were only significant at 6 months (P = 0.037), 1 year (P = 0.038), and 3 years (0.050) between
CDC-FC- and CDC + FC+. CDC, complement dependent cytotoxicity; eGFR, estimated glomerular filtration rate; FC, flow cytometry
Table 3 Rejection pathology and rescue treatments in the patients who experienced biopsy proven rejection within 1 year after
transplantation
Variables CDC − FC−
(n = 42)
CDC − FC+
(n = 11)
CDC + FC+
(n = 8)
P
Median time to BPAR (days) 42 (11–109) 9 (5–31) 14 (5–38) 0.035
Type of acute rejection < 0.001
ABMR 18 (42.9%) 10 (90.9%) 8 (100%)
TCMR 24 (57.1%) 1 (9.1%) 0 (0%)
Rescue treatment < 0.001
Steroid pulse only 16 (38.1%) 0 2 (25.0%)
Steroid pulse + ATG 7 (16.7%) 0 0
PP/IVIG 19 (45.2%) 8 (72.7%) 1 (12.5%)
PP/IVIG + bortezomib 0 3 (27.3%) 5 (62.5%)
ABMR Antibody-mediated graft rejection, ATG Anti-thymocyte globulin, BPAR Biopsy-proven rejection, CDC Complement dependent cytotoxicity, FC Flow
cytometry, IVIG Intravenous immunoglobulin, PP Plasmapheresis, TCMR T-cell medicated rejection
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experienced the highest rate of herpes zoster, PJP, and
CMV infections, and CDC − FC+ patents also experi-
enced more PJP and CMV infections than the controls
(7.3% vs. 7.7% vs. 29.4%, P = 0.046 for herpes zoster; 0%
vs. 2.6% vs. 11.8%, P = 0.001 for PJP; 13.9% vs. 48.7% vs.
64.7%, P < 0.001 for CMV infection; all the rates above
were for CDC − FC− vs. CDC − FC+ vs. CDC + FC+, re-
spectively). No patient died from posttransplant infec-
tion within 1 year.
Discussion
Although patients undergoing crossmatch-positive KT
have the advantage of increased survival compared with
waitlist patients on dialysis, most studies reported that
the outcome was inferior to that of compatible KT [2–4,
19]. In particular, the CDC + FC+ group showed poor
graft survival, which has led to only few institutions per-
forming this procedure. Our institution has actively per-
formed CDC + FC+ KT and CDC-FC+ KT and achieved
graft survival comparable to that of compatible KT with
more advanced DSA-targeted desensitization compared
to that in the present study. However, higher graft rejec-
tion, followed by lower graft function, especially in
CDC + FC+, still warrants attention.
Our desensitization protocol was based on compre-
hensive interpretation of solid phase assays such as SAA
and C1q assay as well as cell-based crossmatch. Marfo
et al. [20] suggested a cutoff for transplantable MFI of
DSA as < 5000 in positive-crossmatch patients who
underwent desensitization, which was also indicated at
our center during the initial period. However, we suc-
cessfully performed KT for patients with higher DSA
levels after desensitization. Although rejection occurred
more frequently, most events were controllable and only
3 positive-crossmatch patients (4.2%) lost their grafts
within 1 year owing to rejection. Furthermore, our indi-
cation for desensitization has been extended beyond the
generally accepted criteria, being as high as T- or B-cell
CDC-positivity titer of 1:32 and five median DSA types
with maximum MFI of > 15,000. Nevertheless, patient
and graft survival of positive-crossmatch KT was almost
parallel to that of compatible KT. This surprising im-
provement was achieved through our DSA-targeted
desensitization protocol and rescue treatment for acute
rejection, especially through a well-planned approach for
patients at very high risk.
The C1q-binding antibody assay has been recently re-
ported as an indicator of allograft survival and respon-
siveness to rejection treatment [7, 21–23]. From August
2013, we monitored the C1q assay in all CDC + FC+
conversion trials and designed more extensive
desensitization methods for C1q-positive patients. Fur-
thermore, we utilized C1q-negative conversion as the
target for successful desensitization and then progressed
to KT.
Bortezomib has been introduced to effectively treat
acute rejection in KT recipients [24–26]. Although it is
uncertain whether bortezomib affects transplantability
alone [27], bortezomib-based desensitization reportedly
reduced anti-HLA DSA and increased the rate of KT in
positive-crossmatch recipients [28]. During the study
period, two patients with T- and B-cell CDC-positivity
and C1q-binding DSA at high MFI level received 4 doses
of bortezomib before transplantation. Despite the higher
strength of DSA than that in patients who underwent
CDC + FC+ KT before, two patients receiving bortezo-
mib not only displayed successful KT outcomes but also
did not experience acute rejection within 1 year after
KT. Recently, we have routinely administered bortezo-
mib for CDC + FC+ KT, expecting increased transplant-
ability and decreased posttransplant acute rejection.
Another strength of our study was the more detailed
comparison of infectious complications than previous
studies among different immunologic risk groups. Al-
though aggressive immunosuppression is inevitable,
limited information is available regarding infectious
complications in positive-crossmatch KT. Two studies
reported that viral infection was increased in positive-
crossmatch KT patients; however, they did not contain a
control group [29, 30]. A recent multicenter study re-
ported that the rates of readmission owing to infectious
complications in both HLA-incompatible group and
control subjects were virtually the same [31]. Further-
more, Okuda et al. [14] reported that bacterial and viral
infections were not different between the positive- and
negative-crossmatch KT groups. However, our study
shows that various infections such as UTIs, bacteremia,
PJP, and CMV infections were significantly more preva-
lent in the positive-crossmatch group than in the com-
patible group. Despite this increased risk of infection,
CDC + FC+ and CDC-FC+ groups showed excellent
Table 4 Infectious complication within 1 year after
transplantation
Variables CDC − FC−
(n = 274)
CDC − FC+
(n = 39)
CDC + FC+
(n = 17)
P
UTI 21 (7.7%) 19 (51.3%) 4 (23.5%) < 0.001
Bacterial pneumonia 4 (1.5%) 2 (5.1%) 0 0.234
Bacteremia 7 (2.6%) 5 (12.8%) 0 0.004
Intraabdominal infection 2 (0.7%) 3 (7.7%) 0 0.003
BKV viremia 18 (6.6%) 2 (5.1%) 0 0.527
Herpes zoster 20 (7.3%) 3 (7.7%) 5 (29.4%) 0.006
PJP 0 1 (2.6%) 2 (11.8%) < 0.001
CMV viremia 38 (13.9%) 19 (48.7%) 11 (64.7%) < 0.001
BKV BK virus, CDC Complement dependent cytotoxicity, CMV Cytomegalovirus,
FC Flow cytometry, PCP Pneumocystis jirovecii pneumonia, UTI Urinary
tract infection
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patient survival. This suggests that positive-crossmatch
KT potentially increases complications, however, they
are controllable and do not increase patient mortality.
Unlike other studies, we excluded patients who
showed CDC-FC- but had pretranspant DSA. The rea-
sons were; 1) relatively small number (n = 21), 2) recent
meta-analysis demonstrating low level DSA detected by
Luminex alone couldn’t affect short to medium post-
transplant outcome [15]. So, we thought that including
those patients would make the analysis complicated ra-
ther than resulted in better risk stratification according
to HLA antibody strength.
The limitation of our study is its retrospective single-
center design with small population and small number
of events. Also, we reported only a 5 year-outcome at
maximum; hence, our results cannot be extrapolated to
long-term setting. Finally, protocol biopsy was not per-
formed in our institution, so we couldn’t compare
chronic pathological results such as chronic ABMR or
chronic allograft nephropathy.
Conclusions
This study showed that intermediate graft and patient
survival after CDC-FC+ and CDC + FC+ KT were im-
proved to levels abreast with those after compatible KT,
using a recent DSA-targeted desensitization protocol.
Higher rejection rates are still a demanding challenge;
thus, improved and specialized desensitization with ad-
vanced immunosuppressive agents is needed.
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